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SIRT6 is a member of a highly conserved family of
NAD+-dependent deacetylases with various roles in
metabolism, stress resistance, and life span. SIRT6-
deficient mice develop normally but succumb to
a lethal hypoglycemia early in life; however, the
mechanism underlying this hypoglycemia remained
unclear. Here, we demonstrate that SIRT6 functions
as a histone H3K9 deacetylase to control the expres-
sion of multiple glycolytic genes. Specifically, SIRT6
appears to function as a corepressor of the transcrip-
tion factor Hif1a, a critical regulator of nutrient stress
responses. Consistent with this notion, SIRT6-defi-
cient cells exhibit increased Hif1a activity and show
increased glucose uptake with upregulation of
glycolysis and diminished mitochondrial respiration.
Our studies uncover a role for the chromatin factor
SIRT6 as a master regulator of glucose homeostasis
and may provide the basis for novel therapeutic
approaches against metabolic diseases, such as
diabetes and obesity.
INTRODUCTION
Adaptation to stress represents a critical cellular response for
maintenance of homeostatic balance. In yeast, the founding
member of the sirtuin family, Sir2, was originally discovered as
a silencing factor, functioning as a sensor of the metabolic
activity of the cell to influence gene transcription, DNA repair,
recombination, and life span (Haigis and Guarente, 2006; Longo
and Kennedy, 2006). Later studies identified Sir2 as an NAD+-280 Cell 140, 280–293, January 22, 2010 ª2010 Elsevier Inc.dependent histone deacetylase, thereby linking chromatin
silencing to cellular redox status.
Inmammalian genomes, there are seven Sir2 homologs (SIRTs
1–7) (Frye, 2000). Little is known about the function of the
mammalian SIRT6 protein. Our previous work has shown that
SIRT6 is a nuclear, chromatin-bound protein (Mostoslavsky
et al., 2006). Among the sirtuins, SIRT6 deficiency causes the
most striking phenotype. SIRT6-deficient mice are born nor-
mally, and at around 3 weeks of age, they develop several acute
degenerative processes, dying before one month of age. The
defects include a severe metabolic imbalance, with low levels
of serum IGF-1, complete loss of subcutaneous fat, lymphope-
nia, osteopenia, and acute onset of hypoglycemia, leading to
death (Mostoslavsky et al., 2006). Furthermore, SIRT6 promotes
the resistance to DNA damage and oxidative stress and sup-
presses genomic instability in mouse cells, in association with
a role in base excision DNA repair (BER) (Mostoslavsky et al.,
2006). Recent studies have demonstrated that SIRT6 is located
at the telomeres in human cells, and knockdown of SIRT6 in
these cells altered the telomere structure, causing accelerated
senescence and telomere-dependent genomic instability.
Furthermore, SIRT6 functions as a histone deacetylase, deace-
tylating histone H3 lysine 9 (H3K9) specifically at telomeres
(Michishita et al., 2008). New studies indicate that SIRT6 can
function as a corepressor of NF-kB, silencing NF-kB target
genes through deacetylation of H3K9 and decreasing NF-kB-
dependent apoptosis and senescence (Kawahara et al., 2009).
Therefore, it appears that SIRT6 can function as a histone
H3K9 deacetylase in a cell- and context-dependent manner. At
this point, however, it remains unclear what the molecular defect
underlying the main phenotype in SIRT6-deficient mice is,
namely the lethal hypoglycemia. Critically, it is not known
whether SIRT6 is directly or indirectly involved in the modulation
of glucose metabolism.
In the presence of O2 and glucose, cells convert glucose to
pyruvate, which enters the mitochondria, is converted to acetyl
coenzyme A, and is metabolized via the tricarboxylic acid cycle
(TCA), yielding reducing equivalents that are used for oxidative
phosphorylation to generate adenosine 50-triphosphate (ATP).
However, under hypoxic or low nutrient conditions, cells shift
their metabolism from aerobic to anaerobic metabolism, con-
verting pyruvate instead to lactate (‘‘Pasteur effect’’) (Aragones
et al., 2009; Vander Heiden et al., 2009). With this energy com-
pensation, cells continue to generate ATP (albeit less efficiently),
in an attempt tomeet their metabolic demands during this period
of stress. The hypoxia-inducible transcription factor Hif1a is a
key mediator of this cellular adaptation to nutrient and oxygen
stress (Lum et al., 2007; Seagroves et al., 2001), functioning
as a direct transcriptional activator of multiple genes. On one
hand, it enhances glycolytic flux by upregulating expression of
key glycolytic genes, including the glucose transporters GLUT-1
and GLUT-3, lactate dehydrogenase (LDH), phosphoglycerate
kinase (PGK-1), glucose-6-phosphate isomerase (GPI), and
phosphofructokinase-1 (PFK-1) (Hu et al., 2006). On the other
hand, Hif1a directly inhibits mitochondrial respiration by upregu-
lating expression of the pyruvate dehydrogenase kinase (PDK)
gene (Kim et al., 2006; Papandreou et al., 2006). PDK in turn
phosphorylates and inactivates pyruvate dehydrogenase (PDH),
a rate-limiting enzyme that converts pyruvate to Acetyl-CoA
to fuel the TCA cycle. Recent studies indicate that Hif1a also
diminishes mitochondrial activity through inhibition of the Cyto-
chrome Oxidase Subunit Cox4-1 and the coactivator PGC-1b
(Fukuda et al., 2007; Zhang et al., 2007). Overall, Hif1a appears
to modulate multiple genes in order to activate glycolysis and
at the same time repress mitochondrial respiration in a coordi-
nated fashion.
The activity of Hif1a is tightly regulated. Under normoxia, Hif1a
is hydroxylated at multiple prolyl residues by the prolyl-hydroxy-
lase-domain (PHD) proteins. Following hydroxylation, Hif1a is
recognized by the von Hippel-Lindau (VHL) ubiquitin ligase,
marking Hif1a for subsequent proteasome degradation. When
O2 or glucose are low, PHD proteins are inactivated, thereby
stabilizing Hif1a protein levels (Aragones et al., 2009). However,
even under normoxic and normoglycemic conditions, Hif1a
regulates basal expression of its target genes (Carmeliet et al.,
1998), suggesting that further mechanisms should be in place
to ensure that this stress response is tightly regulated under
normal nutrient conditions.
We now present data to demonstrate that SIRT6 deficiency
causes a cell-autonomous upregulation of glucose uptake,
both in vitro and in vivo, triggering a nutrient-stress response
and a switch in glucose metabolism toward glycolysis and
away from mitochondrial respiration. We propose that SIRT6
functions as a corepressor of Hif1a transcriptional activity,
deacetylating H3K9 at Hif1a target gene promoters. In this
way, SIRT6 maintains efficient glucose flux into the TCA cycle
under normal nutrient conditions. Regulation of glucose flux by
SIRT6 appears critical because SIRT6 deficiency causes a lethal
hypoglycemia. In this context, it is striking that deficiency in a
single chromatin factor exerts such a severe and specific meta-
bolic phenotype, highlighting the crucial role for SIRT6 in this
pathway.RESULTS
SIRT6 Deficiency Causes a Cell-Autonomous Increase
in Glucose Uptake
Our previous work showed that themost severe defect in SIRT6-
deficient animals is lethal hypoglycemia. Although such a pheno-
type is typically associated with hyperinsulinemia, the mice
exhibit normal pancreatic islets and, remarkably, lower blood
insulin levels, indicating that low glucose may have triggered a
reduction in insulin secretion as an adaptive response (Figures
S1A and S1B available online). In addition, we found that the
mice had no defects in glucose absorption in the intestine and
did not exhibit increased glucose secretion by the kidney (Fig-
ure S1C and data not shown). These observations prompted us
to test whether the mice were experiencing an intrinsic increase
in glucose uptake, independent of insulin levels in blood. We
first took advantage of labeled glucose (1,2-13C Glucose) to
trace glucose in blood. As seen in Figure 1A, SIRT6-deficient
animals clear glucose from blood significantly faster than wild-
type littermates. We next used 18F-fluorodeoxyglucose-positron
emission tomography (FDG-PET) to determinewhich tissues had
increased glucose uptake. We show that SIRT6 mice exhibit
a pronounced increase in glucose uptake in both muscle and
brown adipose tissue (Figures 1B and 1C), whereas no changes
were observed in the liver, brain, or heart (Figure 1C). Further-
more, expression of gluconeogenic genes were higher in SIRT6-
deficient livers (data not shown), further suggesting that liver was
trying to compensate for the hypoglycemia, rather than being
a primary cause of it. This muscle- and BAT-specific increase
in glucose uptake could explain the hypoglycemic phenotype
of SIRT6-deficient mice.
In order to determine whether SIRT6 influences glucose
uptake in a cell-autonomous fashion, we used flow-cytometry to
measure glucose uptake in SIRT6 wild-type (WT) and knockout
(KO) cells using a fluorescent glucose analog (2-NBDG) that
is incorporated into cells and allows quantification of glucose
uptake. Notably, both embryonic stem (ES) cells and mouse
embryonic fibroblasts (MEFs) display a striking increase in
glucose uptake as early as 1 hr following addition of the glucose
analog (Figures 1D and 1E). Furthermore, this effect appears
specific for SIRT6, as SIRT1-deficient MEFs do not show this
phenotype. These results indicate that SIRT6 deficiency causes
increased glucose uptake in a cell-autonomous fashion. It is still
possible that this effect on glucose uptake was secondary to
adaptation to chronic depletion of SIRT6. In order to rule out this
possibility, we generated cells where SIRT6 can be inactivated
in an acute manner. In this system, a previously characterized
dominant-negative form of SIRT6 (Mostoslavsky et al., 2006;
Kawahara et al., 2009) is specifically induced following treatment
with tetracycline. Remarkably, 48 hr after expression of this
dominant-negative mutant, cells exhibit a marked increase in
glucose uptake (Figure 1F).
To definitively demonstrate that the glucose phenotype we
observed was specific to the lack of SIRT6, we re-expressed
SIRT6 in SIRT6 KO ES cells and MEFs and tested whether
glucoseuptakewasnormalized.Re-expressionofSIRT6 rescued
the metabolic phenotype, reducing glucose uptake significantly
(Figure 1G and Figure S1D). In summary, these data show thatCell 140, 280–293, January 22, 2010 ª2010 Elsevier Inc. 281
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lack of SIRT6 in multiple cell types in vivo and in vitro causes
a specific and cell-autonomous increase in glucose uptake.Increased Membrane Expression of the Glucose
Transporter GLUT1 in the Absence of SIRT6
Next we sought to assess whether the increased glucose uptake
in SIRT6-deficient cells was associated with elevated expression
of glucose transporters. The main glucose transporter in ES cells
and MEFs is GLUT1, a receptor that modulates basal uptake
of glucose, independent of growth factors or insulin (Pessin
and Bell, 1992). Therefore, we stained cells with an antibody
against GLUT1 and used confocal microscopy to determine
quantitative differences inmembrane expression of this receptor.
We found that SIRT6 KO cells express substantially higher levels
of membrane GLUT1 (Figures 2A and 2B), consistent with the
increased glucose uptake in these cells.Enhanced Glycolysis and Reduced Mitochondrial
Respiration in SIRT6-Deficient Cells
The above results prompted us to test how glucose is utilized in
SIRT6-deficient cells. We first measured lactate production, in
order to determine whether glycolysis was enhanced. Indeed,
both SIRT6-deficient ES cells (Figure 2C) and MEFs (Figure S2)
display significantly higher levels of lactate when compared to
WT cells. Concomitantly, lack of SIRT6 causes a reduction in
oxygen consumption (Figure 2D), indicating that in SIRT6-
deficient cells glucose is utilized primarily for glycolysis, whereas
mitochondrial respiration is inhibited. To further validate these
results, we performed mass-spectrometry-based metabolic
profiling.Outof106metabolitesanalyzed,22showedaltered levels
in the SIRT6 KO cells (p < 0.05). Among those, we found multiple
TCA metabolites that were reduced in SIRT6 KO cells (Figure 2E),
furtherconfirming thatmitochondrial respiration is inhibited in these
cells. Cells switch to glycolysis in order to sustain ATP production
under conditions of nutrient stress. We therefore tested whether
SIRT6-deficient cellswere fitter thanwild-type cellswhenexposed
to nutrient starvation. Although ATP levels were similar in both cell
typeswhen the cellsweremaintained in normalmedia,SIRT6-defi-
cient cells produce significantly higher levels of ATP after a few
hours in low glucose (Figure 2F). Overall, these results indicateFigure 1. Increased Glucose Uptake in SIRT6-Deficient Cells and Mice
(A) [1,2 13C] labeled glucose trace assay was carried out on 16-day-old SIRT6
details.
(B) Standard uptake value (SUV) ratio of labeled 18FDG-Glucose incorporation in
were normalized against brain, which exhibit stable glucose uptake across gen
(C) 16-day-old SIRT6 WT and KO mice were PET imaged 60 min following intrave
adipose tissue (BAT). *: labeled glucose at site of injection (retro-orbital; the enha
ular CT section; comparable intensity is observed in the KO on a different CT s
(D) SIRT6 WT and SIRT6 KO mouse embryonic fibroblasts (MEFs) together with S
analog NBDG (Invitrogen) for 1 hr, and glucose uptake was then quantified using
glucose analog.
(E) One WT and two independently generated SIRT6 KO ES lines (KO1 and KO2)
(F) 293T cells were stably transfected with a SIRT6 cDNA carrying a H133Y muta
cycline promoter. Lower panel: Western blot showing that SIRT6was induced spe
(Ctrl). Upper panel: glucose uptake was measured as in (D).
(G) SIRT6KOcellswere infectedwith aSIRT6-expressing lentivirus. Infected cellsw
glucose uptake following 1 hr incubation with NBDG.
Error bars indicate the standard error of the mean (SEM). See also Figure S1.thatabsenceofSIRT6causesaswitch towardenhancedglycolysis
and reduced mitochondrial respiration, a response usually
observed under conditions of nutrient/oxygen stress.Glycolytic Genes as Putative SIRT6 Targets in Glucose
Metabolism
Based on the strong binding of SIRT6 to chromatin (Mostoslav-
sky et al., 2006), and the fact that SIRT6 is known to function as
a histone H3K9 deacetylase (Kawahara et al., 2009; Michishita
et al., 2008), we hypothesized that SIRT6 could influence glucose
metabolism by controlling expression of key metabolic genes.
We first performed comparative microarray gene expression
analysis of WT and SIRT6 KO muscle and ES cells (Table S1).
As previously reported (Kawahara et al., 2009), multiple path-
ways appear to be affected in the absence of SIRT6 (Table S1A).
Notably, there is a statistically significant alteration in regulators
of glucose metabolism (Table S1B), and clustering analysis of
metabolic genes separated the samples based on genotype.
When a glucose metabolic filter was applied, the highest dif-
ference was observed among key glycolytic genes, such as
Ldh, triose phosphate isomerase (Tpi), aldolase, and the rate-
limiting glycolytic enzyme phosphofructokinase-1 (Pfk-1). Using
real-time PCR, we validated increased expression of all these
genes in independent RNA samples (Figure 3A). Glut1 was also
increased at the level of RNA, thereby explaining the increased
protein levels described above. Notably, we observed higher
levels of the pyruvate dehydrogenase kinase genes Pdk1 and
Pdk4. As mentioned before, these enzymes phosphorylate and
inhibit PDH, the rate-limiting enzyme that regulates entrance of
pyruvate into the TCA cycle. In brief, our results indicate that in
the absence of SIRT6, expression of multiple glucose-related
genes are upregulated, causing enhanced glycolysis and, in
parallel, inhibition of mitochondrial respiration.SIRT6 Functions as an H3K9 Deacetylase to Regulate
Glucose Homeostasis
In order to test whether SIRT6 directly controls expression
of these genes, chromatin immunoprecipitation (ChIP) was per-
formed using an antibody to SIRT6. As shown in Figure 3B, we
find specific binding of SIRT6 to the promoter of all five of thewild-type (WT) and knockout (KO) mice. See Experimental Procedures for
WT and KO SIRT6 mice. The different tissues analyzed are indicated. Samples
otypes. The experiment is an average of three mice per genotype.
nous (i.v.) injection of 18F-glucose. Dotted lines indicate position of the brown
nced signal observed in the WT reflects the position of the head at this partic-
ection).
IRT1 WT and KO MEFs were grown in the presence of the fluorescent glucose
flow cytometry (FACS). Dotted lines are controls without the fluorescent NBDG
were treated as in (D) and analyzed by FACS.
tion (SIRT6HY) that acts as a dominant negative, under the control of the tetra-
cifically after tetracycline treatment (SIRT6). Empty vector was used as a control
ere sorted forGFPexpression, and following expansion, cellswere assayed for
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Figure 2. Increased Lactate Production and Decreased Oxygen Consumption in SIRT6-Deficient Cells
(A) Confocal immunostaining in SIRT6 WT and KO ES cells using a GLUT1 antibody.
(B) Quantification of GLUT1 membrane staining in SIRT6 WT and KO cells.
(C) Lactate levels in SIRT6 WT and KO ES cells (KO1 and KO2).
(D) Oxygen consumption in live SIRT6 WT and KO ES cells under basal conditions, following the addition of the mitochondrial F1-F0-ATPase inhibitor oligomycin
(5 mM), the uncoupler FCCP (1 mM), and the Complex I inhibitor rotenone (rot) (5 mM) in combination with the Complex I inhibitor myxothiazol (5 mM). Oxygen
consumption rate (OCR) was measured using the XF24 SeaHorse Analyzer (Seahorse Bioscience). Each data point is the average of five independent measure-
ments. Error bars indicate SEM.
(E) Protein lysates were purified from three independent samples of WT and KO ES cells and glucose metabolites were analyzed by liquid chromatography-mass
spectrometry (LC-MS). Red asterisks: TCA intermediate metabolites.
(F) ATP levels were measured using the ATP Assay Kit (SIGMA) in SIRT6 WT and KO ES cells (KO1 and KO2) that were either in regular media or in low glucose
(0.5 g/l) media for 36 hr.
See also Figure S2.most upregulated glycolytic genes identified in our expression
analysis, strongly indicating that SIRT6 functions as a direct tran-
scriptional repressor for thesegenes.Previousworkhas identified
SIRT6 as a histoneH3K9 deacetylase (Michishita et al., 2008).We
have confirmed these results and further show that lack of SIRT6
causes a bulk increase inH3K9acetylation in EScells, suggesting
that SIRT6 is one of the main H3K9 deacetylases in these cells
(Figure S3). Therefore, we tested whether SIRT6-deficient cells
exhibit increased H3K9 acetylation in the promoters of these
glycolytic genes. Indeed, ChIP analysis with an anti-H3K9Ac
antibody clearly shows increased acetylation in all these putative
targets (Figure 3C). Together, these results strongly suggest
that SIRT6 directly suppresses expression of multiple glucose-
metabolic genes by deacetylating H3K9 at their promoters.
To gain insight into the mechanism by which SIRT6 modulates
expression of these genes, we chose one of these targets, Ldhb,
to perform high-resolution, quantitative ChIP analysis. Using
qPCR amplicons against eight different locations within this
genomic region, we analyzed the behavior of RNA polymerase
II (RNAPII) in WT cells versus SIRT6 KO cells. We employed284 Cell 140, 280–293, January 22, 2010 ª2010 Elsevier Inc.antibodies against total RNAPII as well as phospho-specific anti-
bodies recognizing phosphorylation of Ser5 and Ser2 within the
C-terminal domain (CTD) repeats of RBP1, the largest subunit of
RNAPII (Donner et al., 2007). Interestingly, this analysis revealed
that in WT cells the Ldhb promoter carries preloaded hypophos-
phorylated RNAPII and that SIRT6 depletion leads to increased
RNAPII CTD phosphorylation concomitant with enhanced tran-
scription elongation (Figure 3D). Whereas RNAPII was readily
detectable at the LDHB transcription start site (TSS) in WT and
SIRT6 KO cells, transit throughout the intragenic region was
observed only in the latter. Furthermore, total RNAPII signals at
the TSS were several-fold higher than at any amplicon in the
intragenic region, a hallmark of RNAPII pausing at the promoter.
Typically, Ser5 phosphorylation occurs at the 50 ends of genes
and is associated with promoter escape by RNAPII. Accordingly,
SIRT6 KO cells show significantly higher levels of this mark. Of
note, the fold increase in Ser5 phosphorylation surpasses that
of total RNAPII, indicating that in WT cells preloaded RNAPII
exists in a hypophosphorylated state. The fact that Ldhb tran-
scription is stimulated at post-RNAPII recruitment steps is
Figure 3. SIRT6 Directly Inhibits Expression of Glycolytic Genes Functioning as an H3K9 Deacetylase
(A) RNA was purified from SIRT6 WT and KO ES cells and real-time PCR (RT-PCR) was performed with primers specific for the indicated genes. Three indepen-
dent samples were averaged, keeping a threshold of 0.4 as confidence value in the threshold cycle (Ct). Values were normalized against actin.
(B) Chromatin immunoprecipitation (ChIP) assays using an antibody against SIRT6 were performed on samples from SIRT6 WT and KO ES cells. RT-PCR were
carried out using primers specific for the promoter regions of the indicated glycolytic genes, except for Ldha-1Kb, where primers lying 1 kb downstream of the
30UTR of the Ldha gene were used and served as a negative control.
(C) ChIP assays were performed as described in (B), with an anti H3K9 acetylated antibody (Abcam). The Ldha-1kb primers were used as a negative control.
(D) High-resolution ChIP analysis was performed in the Ldhb locus using antibodies against total RNA polymerase II (RNAPII), phosphorylated serine 5 form of
RNAPII (S5P-CTD), phosphorylated serine 2 form of RNAPII (S2P-CTD), and acetylated H3 lysine 9. Error bars in all graphs indicate SEM.
See also Table S1 and Figure S3.
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Figure 4. SIRT6 Is a Corepressor of Hif1a
(A) A luciferase reporter gene under the regulation of three tandem copies of Hypoxia-Responsive Elements (HRE) was cotransfected with empty vector (CMV),
SIRT6 (S6), or SIRT6-HY (catalytic dead) plasmids into 293T cells and subjected to low-glucose (5mM) conditions for 24 hr. Extracts were analyzed for Luciferase
activity. Error bars indicate SEM.
(B) Left panel: A Flag control, a SIRT6-Flag, or a SIRT1-Flag protein was either expressed alone or coexpressedwith Hif1a-Myc in 293T cells, and following immu-
noprecipitation (IP) with either a Flag, a Myc, or an IgG antibody, extracts were analyzed by western blot and probed with the indicated antibodies. Right panel:
Lysates were prepared from SIRT6WT and KOmuscle, and following IP with anti-Hif1a antibody, extracts were analyzed by western blot probed with anti-SIRT6
antibody. The IgG band is shown as loading control.
(C) Lysates were prepared from SIRT6 WT or KO ES cells, followed by IP and western blot with a Hif1a antibody.
(D) ES cells (left panel) or 293T cells stably expressing a tetracycline-inducible SIRT6 dominant-negative allele (S6HY) (right panel) were treated with or without the
Hif1a inhibitor #77 (Zimmer et al., 2008) and glucose uptake was measured by FACS, following 1 hr exposure to NBDG.
See also Figure S4.reinforced by analysis of Ser2 phosphorylation, a mark of
actively elongating RNAPII that is increased several fold in
SIRT6 KO cells. Consistent with our conventional ChIP results
(Figure 3C), we also observe higher H3K9 acetylation in this
assay. It is, however, of interest that this increase occurs focally,
close to the TSS, without spreading to nearby regions. Overall,
these results indicate that SIRT6 action represses transcription
of Ldhb (and arguably the other target genes) at regulatory steps
downstream of RNAPII recruitment.
SIRT6 Functions as a Corepressor of Hif1a
Our results thus far indicate that SIRT6 might play a role in redi-
recting carbohydrate flux from glycolysis to mitochondrial
respiration, and in the absence of SIRT6, glycolysis is enhanced
and the TCA cycle inhibited, a phenotype usually observed as an
adaptation against nutrient or oxygen deprivation. One of the
main positive regulators of this switch is the transcription factor
Hif1a. In this context, all the genes that were upregulated in the
SIRT6-deficient cells are direct targets of Hif1a. Therefore, we286 Cell 140, 280–293, January 22, 2010 ª2010 Elsevier Inc.decided to test whether SIRT6 could function to modulate a
Hif1a nutrient stress response. First, we tested whether SIRT6
could influence expression of a luciferase reporter carrying
multiple Hypoxia-Responsive Elements (HREs), the consensus
binding sequence for Hif1a. This construct is specifically acti-
vated following low glucose/hypoxia, and thus it represents a
direct measurement of Hif1a activation in these cells (Zimmer
et al., 2008). As shown in Figure 4A, exposing the cells to 24 hr
low glucose elicited robust luciferase activity, and notably SIRT6
coexpression causes significant repression. Such an effect was
not observed when we overexpressed a catalytically inactive
mutant of SIRT6, suggesting that the enzymatic activity of SIRT6
was required for this specific effect on the promoter.
As Hif1a appears to maintain basal activity even under normo-
glycemia (Carmeliet et al., 1998), we hypothesized that SIRT6
might bind Hif1a at the chromatin to regulate its activity. In order
to test whether SIRT6 and Hif1a interact, FLAG-tagged SIRT6
was coexpressed with Myc-tagged Hif1a in 293T cells. Western
analysis of the IPs revealed that Myc-Hif1a coprecipitated with
SIRT6 and, likewise, FLAG-SIRT6 coprecipitated with Hif1a
(Figure 4B). This interaction appears specific, as other FLAG-
sirtuins, like SIRT1, did not interact with Hif1a under these condi-
tions (Figure 4B). In order to confirm that these proteins interact
under physiological conditions, we immunoprecipitated Hif1a
frommuscle and testedwhether SIRT6 coprecipitated. As shown
in Figure 4B, SIRT6 was readily detected in the Hif1a IP, clearly
indicating that endogenous Hif1a and SIRT6 can interact.
Conditions of nutrient and oxygen stress cause activation of
Hif1a, with increased protein levels due to both protein synthesis
and stabilization of the protein (Aragones et al., 2009). As lack
of SIRT6 mimics a nutrient stress response, we determined
whether SIRT6-deficient cells exhibit increased levels of Hif1a.
Extracts were purified from SIRT6 WT and KO cells grown under
normoglycemic conditions, and western blot analysis was per-
formed with an antibody specific for Hif1a. As expected for a
normoglycemic condition, Hif1awas barely detected inWT cells.
In contrast, Hif1a was readily detected in SIRT6 KO cells (Fig-
ure 4C). These results strongly indicate that under normal
nutrient conditions, SIRT6 plays an important inhibitory role upon
Hif1a-dependent glucose-related gene transcription, and lack of
SIRT6 is sufficient to upregulate glycolytic gene transcription.
Downregulation of Hif1a Rescues the Metabolic
Phenotypes in SIRT6-Deficient Cells
The above results suggest that lack of SIRT6 triggers a Hif1a-
dependent metabolic switch. In order to test whether Hif1a plays
a critical role in this phenotype, we decided to inhibit Hif1a in
SIRT6 KO cells and test whether we could rescue the metabolic
abnormalities observed in these cells. For this purpose, we first
treated SIRT6 KO ES cells with a recently described small-mole-
cule inhibitor of Hif1a/Hif2a (Zimmer et al., 2008). Treatment with
this inhibitor for 24 hr was sufficient to completely revert the
glucose uptake increase in SIRT6 KO cells (Figure 4D, left panel).
This effect appears specific, as the compound did not affect WT
cells. Furthermore, treatment with AKT or mTOR inhibitors, both
modulators of insulin signaling and stress responses, was not
able to rescue the metabolic phenotype (Figure S4), strongly
indicating that SIRT6 modulates glucose homeostasis specifi-
cally through a Hif1a-dependent pathway. To further validate
these results, we performed a similar experiment in the inducible
SIRT6 dominant-negative cells, where we previously showed
that acute inactivation of SIRT6 leads to increase glucose uptake
(Figure 1F). Similar to what we observed in the KO ES cells, treat-
ment with the Hif1a inhibitor readily decreased glucose uptake in
these cells as well (Figure 4D, right panel).
In order to confirm the role of Hif1a in this phenotype, we
specifically knocked down Hif1a in SIRT6-deficient cells. We
grew multiple independent ES clones obtained following infec-
tion with a shRNA-Hif1a virus. Notably, in those clones where
Hif1a was downregulated, the increased glucose uptake was
completely rescued (Figure 5A, clones #1 and #2). This effect
is specific, as WT cells show no effect upon Hif1a knockdown.
Furthermore, in those few clones where the Hif1a knockdown
failed (as an example, see clone #3, Figure 5A), we observed
no changes in glucose uptake. To test at the transcriptional level
the critical modulators of this rescue, we purified RNA from the
SIRT6 KO/Hif1a knockdown cells and analyzed expression ofthe glycolytic genes previously identified. Notably, expression
of most of these glycolytic genes was rescued to the levels
observed in WT cells (Figure 5B). One exception is Pdk1, which
exhibits no statistical differences between the parental SIRT6 KO
and the Hif1a knockdown cells, suggesting that in this case, the
Pdk4 isoform plays a more dominant role.
Taking advantage of these Hif1a knockdown cells, we tested
whether Hif1a was required to recruit SIRT6 to these glycolytic
gene promoters. For this purpose, ChIP with anti-SIRT6 anti-
bodies was performed in these cells, and SIRT6 occupancy on
those promoters evaluated. As seen in Figure 5C, lack of Hif1a
significantly reduced SIRT6 binding to these promoters, indi-
cating that SIRT6 is specifically recruited to these promoters
via its physical interaction with Hif1a.
Lack of SIRT6 Increases Both Protein Synthesis
and Stability of Hif1a
In order to gain further insight into the increase levels of Hif1a
that we observed in our SIRT6-deficient cells, we first tested
whether SIRT6 directly regulates Hif1a. For this purpose, we
analyzed RNA levels in SIRT6-deficient cells. As shown in Fig-
ure 6A, Hif1a RNA levels were comparable between WT and
KO cells, indicating that Hif1a is not a direct transcriptional target
of SIRT6. Previous studies have indicated that Hif1a could itself
be acetylated (Jeong et al., 2002). However, such findings were
later disputed (Arnesen et al., 2005; Murray-Rust et al., 2006). In
this context, we also failed to detect Hif1a acetylation in vivo,
even in SIRT6 KO cells, where total levels of Hif1a were signifi-
cantly higher (Figure S5); therefore, a direct effect for SIRT6 on
Hif1a appears unlikely. We next tested whether protein stability
of Hif1a was increased in the SIRT6 KO cells. For this purpose,
we treated cells with the iron chelator CoCl2, which inhibits the
activity of the prolyl-hydroxylases, therefore inhibiting degrada-
tion of Hif1a. Whereas treatment with the drug robustly increase
Hif1a in WT cells, this effect was significantly diminished in the
SIRT6 KO cells (Figure 6B), indicating that in these cells Hif1a
is already stabilized. However, some increase was observed
in the KO cells, suggesting that increased stability could only
partially account for the higher levels observed in these cells.
We therefore tested whether Hif1a protein synthesis was also
enhanced in the absence of SIRT6. We first took advantage
of a previously described luciferase reporter carrying the 50
untranslated region (UTR) of the Hif1a gene (Bert et al., 2006).
Notably, SIRT6 KO cells exhibit a significant increase in lucif-
erase activity under basal conditions, similar to the levels
observed inWTcells following nutrient/oxygen stress (Figure 6C).
As an independent assay, we purified the polysomes fraction of
ribosomes and quantified the rate of Hif1a translation in both WT
and KO cells (Serikawa et al., 2003). Consistent with the previous
assay, SIRT6 KO cells exhibit a clear increase in Hif1a translation
in this assay as well (Figure 6D). Altogether, these results indicate
that both Hif1a protein synthesis and stability are increased in
SIRT6-deficient cells.
IncreasedExpression ofGlycolytic Genes and Increased
Lactate Production in SIRT6-Deficient Mice
We next tested whether this glycolytic switch that we observed
in vitro was also responsible for the metabolic phenotypeCell 140, 280–293, January 22, 2010 ª2010 Elsevier Inc. 287
Figure 5. Knocking down Hif1a Completely Rescues the Metabolic Phenotype in SIRT6-Deficient Cells
(A) SIRT6 WT and KO ES cells were infected with either a Hif1a knockdown lentivirus (shHif1a) or vector alone (scr). Independent clones were expanded, and
glucose uptake was measured using NBDG, as described before. Lower right panel: Western blot analysis of the different clones with an anti-Hif1a antibody.
Note that clone #3 failed to downregulate Hif1a, and thus it served as an internal control.
(B) RNAwas purified fromHif1a knockdown clones and glycolytic gene expression levels were examined by RT-PCR. The different analyzed genes are indicated.
Fold induction was normalized against actin. Three independent samples were averaged, keeping a threshold of 0.4 as confidence value in the threshold cycle
(Ct). Error bars in all graphs indicate SEM.
(C) Hif1a recruits SIRT6 to the glycolytic promoters. ChIP was performed on wild-type control (WT-ctrl) and Hif1a knockdown cells (WT-shHif) with an antibody
against SIRT6. RT- PCR were carried out using primers specific for the promoter region of the Ldhb gene. SIR6 KO cells were used as negative controls in the
ChIP assay.observed in vivo. Protein extracts were purified from muscle of
multiple SIRT6 WT and KO mice, and westerns were performed
with antibodies against the different glycolytic enzymes. Strik-
ingly, the two rate-limiting factors PFK-1 and PDK1, which were
barely detectable in WT muscle, were expressed at very high
levels in SIRT6 KO muscle (Figure 7A). As well, we observed
higher levels of other glycolytic genes, such as TPI1, whereas
expression of the p53 target TIGAR, which was recently shown
to inhibit glycolysis (Bensaad et al., 2006), was reduced in the
KO samples. Using immunostaining, we then tested for expres-288 Cell 140, 280–293, January 22, 2010 ª2010 Elsevier Inc.sion of the GLUT1 transporter. Similar to what we found in ES
cells, muscle but not brain from SIRT6-deficient animals ex-
pressed significantly higher levels of GLUT1 (Figure 7B). Finally,
we tested whether lactate production was increased in the KO
animals. As shown in Figure 7C, SIRT6 KO animals exhibit a
modest but statistically significant increase in serum lactate,
when compared to WT animals, thus supporting the argument
that lack of SIRT6 in vivo promotes uncontrolled glucose
uptake and a glycolytic switch, consistent with our findings
in vitro.
Figure 6. Increased Hif1a Stability and Protein
Synthesis in SIRT6-Deficient Cells
(A) RNA was purified from SIRT6 WT and KO ES cells and
Hif1a expression was analyzed by RT-PCR using primers
specific for the mRNA of Hif1a. Results are shown as the
mean ± SEM (n = 6).
(B) Upper panel: Lysates were prepared from SIRT6 WT
or KO ES cells, followed by IP and western blot with a
Hif1a antibody. Samples were either left untreated or
treated with the Hif1a stabilizer CoCl2 (150 mM) for 24 hr
prior to lysatepreparation.Lowerpanel:Quantitativedensi-
tometric analysis of Hif1a levels from the upper panel blot.
(C) Wild-type (WT) and SIRT6-deficient (KO) cells were co-
transfected with an empty 50UTR-Luc vector or Hif1a
50UTR-Luc reporters and shifted 6 hr post-transfection
to no glucose-hypoxia conditions for 24 hr for measure-
ment of luciferase activity.
(D) Polysome profile analysis of WT and Sirt6-deficient
(KO) ES cells. Lower panel: WT and KO cells were treated
with cycloheximide (CHX) for 10 min before collection.
The lysates were processed for polysome analysis by
velocity sedimentation on sucrose gradients. Gradients
were fractionated by scanning at 254 nm, and the result-
ing absorbance profiles are shown with sedimentation
from left to right. Upper panel: Quantitative RT-PCR was
performed to assess distribution of HIF1a mRNA.
Error bars in all graphs indicate SEM. See also Figure S5.Hif1a Inhibition Rescues the Glucose Phenotype
in SIRT6-Deficient Mice
To test whether the hypoglycemia observed in the SIRT6-defi-
cient animals was dependent on Hif1a, as we found in vitro,
we treated SIRT6-deficient animals with the Hif1a inhibitor
described above. Strikingly, treatment with the drug caused
a fast and specific increase in blood glucose levels specifically
in the KO animals (Figure 6D). These results indicate that, similar
to what we observed in our SIRT6 KO ES cells, regulation of
glucose metabolism by SIRT6 depends on Hif1a in vivo as well.
DISCUSSION
Our studies reveal that SIRT6 functions as a histone deacetylase
to control glucose homeostasis by inhibiting multiple glycolytic
genes in a coordinated fashion (Figure 7E). Under conditions
of normal glucose availability, SIRT6 represses expression of
key enzymes, diverting pyruvate toward the mitochondrial TCA
cycle for efficient ATP production. At those promoters, SIRT6
competes with the transcriptional activator Hif1a to maintain
proper glucose flux toward mitochondrial respiration and to
prevent excessive glycolysis. Several lines of evidence support
this model. First, SIRT6 deficiency causes upregulation of glyco-
lytic genes at the level of expression, a finding that is accompa-
nied by increased glucose uptake and a switch toward glycolysis
even under normal nutrient conditions (Figures 1, 2, and 3).
Second, SIRT6 directly binds to the promoters of these genes,Cell 140, 28and in the absence of SIRT6, H3K9 acetylation
increases specifically in those promoters
(Figures 3B–3D). Third, we find that SIRT6 influ-
ences glycolysis as a corepressor of Hif1a, and
in the absence of SIRT6, the glycolytic pheno-type can be rescued by knocking down Hif1a in these cells
(Figures 4 and 5). Thus, SIRT6 acts as a safeguard mechanism
to downmodulate basal transcription of Hif1a target genes under
normal nutrient conditions (Carmeliet et al., 1998). In this context,
there are two plausible scenarios. The first possibility is that
SIRT6 binding to the promoters inhibits recruitment of Hif1a
(accelerating its degradation). Alternatively, Hif1a could already
localize to the promoters under normoglycemia, but the pres-
ence of SIRT6 would inhibit its transcriptional activity. Even
though we found that SIRT6 and Hif1a can interact (Figure 4B),
we were unable to perform ChIP assays with anti-Hif1a anti-
bodies; therefore, we cannot rule out at present either possibility.
However, recent studies have shown that, indeed, Hif1a
occupies its target promoters even under normoxia (Xia et al.,
2009), supporting our second model. Notably, early studies
have demonstrated that Hif1a activates transcription through
recruitment of the histone acetyl-transferase p300/CBP (Arany
et al., 1996; Kallio et al., 1998); consequently, SIRT6 might
compete against recruitment of p300, maintaining histones in
those promoters in a hypoacetylated state. Future studies will
likely address this possibility. In the context of the Hif1a knock-
down experiments, it is intriguing that despite full rescue of the
metabolic phenotype (see Figure 5A), only a subset of glycolytic
genes were rescued (Figure 5B, see for instance Pdk1). These
results suggest that although SIRT6 regulates multiple glycolytic
genes in a coordinated fashion, only few of them play a dominant
role in this glycolytic switch.0–293, January 22, 2010 ª2010 Elsevier Inc. 289
Figure 7. Hif1a-Dependent Increased Glycolysis and Lactate Production in SIRT6-Deficient Mice
(A) Lysates were prepared frommuscles of four littermate pairs of SIRT6WT and KOmice. Western analysis was carried out with antibodies against the indicated
proteins. Tubulin was used as a loading control.
(B) Immunostaining with a GLUT1 antibody (green) was carried out on muscles and brain from SIRT6 WT and KO mice. Nuclei were stained with DAPI (blue).
Images were taken using a confocal microscope with constant laser beam for all images (KR: 39.8; IRIS: 2.0).
(C) Serum was purified from SIRT6 WT and KO mice, and lactate was measured using the Lactate Assay Kit (BioVision). Error bars indicate SEM; n = 4 for each
genotype.
(D) A Hif1a small-molecule inhibitor rescues the glucose phenotype in SIRT6-deficient mice. Hif1a inhibitor #77 (20 mg/g weight) was injected intraperitoneally
(i.p.) in 19-day-old WT and SIRT6 KO mice, and 30 min later blood was withdrawn for glucose measurement. Five percent DMSO (dilution solution) was injected
as control.
(E) Model. Under normal nutrient conditions, SIRT6 inhibits expression of glycolytic genes acting as an histone deacetylase to corepress Hif1a. This maintains
proper flux of glucose to the TCA cycle. Under conditions of nutrient stress, SIRT6 is inactivated, allowing activation of Hif1a, recruitment of p300, acetylation of
H3K9 at the promoters, and increased expression of multiple metabolic genes, causing increased glycolysis and decreased mitochondrial respiration.
See also Figure S6.An alternative explanation to our results would be that, in addi-
tion to deacetylating histones at those putative targets, SIRT6
actually regulates Hif1a itself. In this regard, we find no changes
in Hif1aRNA levels in SIRT6-deficient cells (Figure 6A), indicating
that SIRT6 does not regulate expression of this factor. A second
possibility would be that SIRT6 deacetylates Hif1a, and in the
absence of SIRT6, Hif1a is acetylated and stabilized. However,
as shown above, we also failed to detect Hif1a acetylation
in vivo, even in SIRT6 KO cells, where total levels of Hif1a were290 Cell 140, 280–293, January 22, 2010 ª2010 Elsevier Inc.significantly higher (Figure S5A); therefore, a direct effect for
SIRT6 on Hif1a appears unlikely. On the other hand, we find
that lack of SIRT6 increases both protein synthesis and protein
stability of Hif1a. Previous studies have shown that conditions
of nutrient stress and increase in lactate production can function
as a positive feedback to induce both protein synthesis and
stability of Hif1a (Lu et al., 2002; Hirota and Semenza, 2005).
Although at present other possibilities cannot be ruled out,
SIRT6-deficient cells experienced both nutrient stress and
increased lactate production, likely explaining the increased
Hif1a levels observed in these cells.
Using high-resolution quantitative ChIP mapping of the LDHB
gene, we gained further insight into the molecular mechanisms
of SIRT6 silencing. Our results indicate that in wild-type cells,
SIRT6 binding maintains low levels of H3K9 acetylation at the
LDHB promoter, thereby inhibiting transcription, despite the
presence of preloaded RNAPII. In the absence of SIRT6, tran-
scription is activated, as indicated by robust enrichment of Ser5-
and Ser2-phosphorylated RNAPII, markers of promoter escape
and transcriptional elongation, respectively. These results are
intriguing, suggesting that SIRT6, a histone deacetylase, might
repress transcription at a stage downstream of RNAPII recruit-
ment. Recent studies have shown that engaged but paused
polymerase plays an important role on genes that need to be
rapidly activated (Core and Lis, 2008). Changes in nutrient condi-
tions could vary rapidly, and therefore, it is tempting to speculate
that SIRT6 could repress transcription while maintaining an
engaged polymerase, which in turn will allow rapid activation
of transcription at these glycolytic genes upon changes in
nutrient availability. Whether this represents a general epigenetic
mode of regulation remains to be determined.
Recent studies have shown that SIRT6 can function as a core-
pressor of NF-kB, modulating expression of NF-kB targets
(Kawahara et al., 2009). Furthermore, RelA haploinsufficiency
was able to rescue the lethality of SIRT6-deficient animals.
However, glucose levels in these animals remain low for the first
weeks of life. Therefore, it is unlikely that NF-kB represents the
initial trigger in the hypoglycemic phenotype observed. Consis-
tent with this notion, we do not observe changes in expression
of NF-kB targets in our muscle-microarray data (Table S1A).
Overall, these results strongly support amodel where the defects
in glucose metabolism observed in the absence of SIRT6 stem
from its role in controlling glycolytic gene expression rather
than through modulation of NF-kB targets.
Our model for SIRT6 function predicts that under conditions
of nutrient stress, SIRT6 would be inactivated, triggering
a Hif1a-dependent glycolytic switch, similar to what we
observed in our SIRT6-deficient cells (Figure 7E). In this regard,
we do not observe changes in total levels nor in localization of
SIRT6 protein following glucose deprivation (Figure S6). One
possibility is that SIRT6 activity is controlled at a posttranscrip-
tional level, an alternative that is under current investigation. It
is interesting that nutrient deprivation has been shown to
increase levels of another mammalian sirtuin, SIRT1 (Cohen
et al., 2004; Nemoto et al., 2004), indicating that these proteins
might have evolved to function in contrasting scenarios. In this
context, whereas SIRT1 activators have been shown to protect
against metabolic diseases such as type II diabetes, as pub-
lished (Baur et al., 2006; Lagouge et al., 2006; Milne et al.,
2007), in the case of SIRT6, inhibition rather than activation
might prove beneficial to lower blood glucose in metabolic
diseases.
The increased glycolytic capacity and reduced oxidative
phosphorylation we observe in SIRT6-deficient cells are reminis-
cent of the ‘‘Warburg effect’’ described by Otto Warburg several
decades ago (Warburg, 1956). Such a phenomenon describes
the peculiarity that most cancer and highly proliferative cellsrely on aerobic glycolysis rather than respiration for their energy
and metabolic needs (Vander Heiden et al., 2009). Consistent
with our observations in SIRT6-deficient cells, recent studies
indicate that aerobic glycolysis requires Hif1a as well (Lum
et al., 2007), and Hif1a confers resistance to apoptosis in cancer
cells under hypoxic conditions in a GLUT1-dependent manner
(Kilic et al., 2007). Based on this analogy, one could predict
that lack of SIRT6 should provide an advantage for tumorigenic
growth. In this context, SIRT6-deficient ES cells exhibit
increased resistance to apoptosis when exposed to hypoxia/
hypoglycemia (Figure S5B); however, we are currently unable
to test this hypothesis in vivo, as SIRT6-deficient animals die
early in life. Although it remains unclear what the trigger is that
allows the switch from oxidative phosphorylation to aerobic
glycolysis (Vander Heiden et al., 2009), our results indicate
that inhibition of SIRT6 might be an important player.
Previous studies in yeast, worms, and flies have linked Sir2
proteins to the regulation of longevity (Finkel et al., 2009; Longo
and Kennedy, 2006; Yu and Auwerx, 2009). Whether such a role
is conserved in mammals remains unclear. However, multiple
lines of evidence indicate a critical role for some of these
mammalian sirtuins in regulating metabolic homeostasis (Canto
et al., 2009). As changes in calorie intake and metabolic balance
has been previously linked to life-span regulation in mammals
(Yu and Auwerx, 2009; Barzilai and Bartke, 2009), our new
results with SIRT6 place this chromatin deacetylase as a poten-
tial candidate among sirtuins to influence aging and age-related
diseases. Notably, two recent articles have shown that Hif1a can
modulate life span in C. elegans (Chen et al., 2009; Mehta et al.,
2009). Whether this is the case in mammals remains unknown;
however, our results suggest that sirtuins and Hif1amay function
in a coordinated fashion to modulate metabolic homeostasis in
higher eukaryotes.
Overall, our studies have demonstrated a role for the histone
deacetylase SIRT6 in controlling glucose homeostasis. The
severe metabolic phenotypes we observed indicate that among
themammalian sirtuins, SIRT6 appears to play a dominant role in
regulating energy balance. They also suggest that although a
glycolytic switch might be an important acute adaptive response
in situations of nutrient stress or cancer growth, chronic and
sustained activation of this switch (as in the case of SIRT6
deficiency) is rather detrimental.
EXPERIMENTAL PROCEDURES
Western and Immunostaining Analysis
Western analysis was carried out as previously described (Cheng et al., 2003).
The antibodies used are as follows: anti-SIRT6 (Abcam), anti-Hif1a (Novus),
anti-Flag (Sigma), anti-PFK-1 (Abcam), anti-PDK1 (Abcam), anti-TPI1 (Protein-
tech), anti-TIGAR (Abcam), anti-Tubulin (Sigma). For immunostaining of ES
cells, cells were grown on coverslips and fixed with 4%paraformaldehyde and
permabilized with 0.1% Triton X-100 in PBS as described (Bassing et al.,
2002). Cells were stained with anti-Glut1 antibody (Alpha Diagnostic). Images
were taken using a confocal microscope with constant laser beam for all
images (KR:39.8; IRIS:2.0).
Lactate and Oxygen Consumption Assays
Lactate concentration was determined with the Lactate Assay Kit (BioVision).
Optical density (OD) was measured at 570 nm, 30 min after addition of
substrate. For oxgen consumption, 4 3 105 SIRT6 WT and KO ES cells wereCell 140, 280–293, January 22, 2010 ª2010 Elsevier Inc. 291
seeded, and 24 hr oxygen consumption rate was measured with the Seahorse
XF24 instrument (Seahorse Bioscience), as published (Liu et al., 2009).
Metabolite Analysis
SIRT6 wild-type and KO cells were grown under normal nutrient conditions,
and methanol-fixed proteins were analyzed by liquid chromatography-mass
spectrometry (LC-MS), as described (Lewis et al., 2008).
Glucose Uptake Assays in Mice and in Cells
For the assessment of in vivo glucose disposal, [1,2-13C] glucose was IP in-
jected (2 mg/gm body weight) into mice (n = 4). Blood samples were collected
30 min after and processed for GC/MS analysis as previously described
(Xu et al., 2004). For the glucose uptake assay in mice, 16-day-old SIRT6
WT and KO mice were imaged using a Siemens Inveon PET-CT 45 min
post-injection of approximately 500 uCi of FDG, as published elsewhere
(Boiselle et al., 1998). For glucose uptake assays in cells, cells were grown
under normal conditions for 24 hr and 100 mM 2-NBDG (Invitrogen) was
added to the media for 2 hr. Fluorescence was measured in a FACSCalibur
Analyzer (BD).
ATP Concentration Assays
SIRT6 WT or KO ES cells were grown in low glucose (0.5 g/l) media for 24 hr
and ATP concentration was measured by ATP bioluminescent somatic cell
assay kit (Sigma) per manufacturer instructions.
Luciferase Reporter Assays
13 105 293T cells were transfected using Trans-IT 293 (Mirus) with 1 mg of the
following plasmids as described in the text: pGL3::HRE4, pCMV-3xF-SIRT6
and pCMV-3xF-SIRT6HY. Twenty-four hours after transfection, cells were
harvested and luciferase activity was determined using the Dual-Luciferase
Reporter Assay system (Promega).
ChIPs and Quantitative RT-PCR
ChIP and qRT-PCR were performed as previously described (Donner et al.,
2007). The antibodies and the primers’ sequences for all the RT-PCRs are
included in Extended Experimental Procedures and Table S1.
Retroviral Infection
SIRT6 WT cDNA was amplified by PCR and cloned into the pHAGE2-EF1a-
dsRed-IRES-tomato vector. Hif1a shRNA lentivirus vectors were obtained
from The RNAi Consortium Library (MGH). SIRT6 WT and SIRT6 KO ES cells
were infected by incubating with virus and 10 mg/ml polybrene. Forty-eight
hours later, cells were selected in 2.5 g/ml puromycin and single colonies
were picked and plated for various experiments.
50UTR Assays
SIRT6 WT and KO ES cells were transfected using Lipofectamine 2000 with
a luciferase vector lacking 50UTR as control and a vector with a partial HIF1a
50UTR (kindly provided by Gregory J. Goodall) cotransfected with the Renilla
Luciferase plasmid. Six hours post-transfection media were changed to
normal or no glucose and incubated in 1% Oxigen chamber for 24 hr. Protein
was extracted as detailed in the promega kit for Dual Luciferase Assay per
manufacturer instructions. Luminescence was read at 500 nm.
Polysome Profiling Analysis
Cytoplasmic extracts were purified from cycloheximide-treated SIRT6WT and
KO ES cells. The lysates were processed for polysome analysis by velocity
sedimentation on sucrose gradients. Quantitative RT-PCR was performed
on purified mRNA to assess distribution of HIF1a mRNA, which was normal-
ized to 18S mRNA. For details, see Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and one table and can be found with this article online at doi:10.1016/
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